Achieve Life Sciences (ACHV) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 118.1% versus a loss of 6.0%. Over five years, ACHV leads with a -10.1% price change compared with -94.9% for IMDX. Achieve Life Sciences is the larger company by market cap ($746.5 million vs $113.2 million), about 6.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | IMDX |
|---|---|---|
| Share price | $7.24 | $3.46 |
| Market cap | $746.46M | $113.23M |
| 1-day change | +2.99% | +2.37% |
| YTD return | +45.67% | -53.87% |
| 1-year return | +118.07% | -5.98% |
| 5-year return | -10.06% | -94.91% |
| EPS (TTM) | $-1.69 | $-1.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $8.51 |
| 52-week low | $2.62 | $2.42 |
| Distance from 52-week high | -16.20% | -59.34% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +95.44% | — |
| Average volume | 1.45M | 234.39K |
| Shares outstanding | 103.10M | 32.72M |
| Employees | 28 | — |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Achieve Life Sciences is about 6.6 times larger than Insight Molecular Diagnostics by market value ($746.46M vs $113.23M).
- ACHV has outperformed IMDX by 124.1 percentage points over the past year.
- The two companies sit in different sectors: Achieve Life Sciences in Healthcare and Insight Molecular Diagnostics in Health Care.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Healthcare · Biotechnology · 28 employees
ACHV vs IMDX FAQ
Which is bigger, Achieve Life Sciences or Insight Molecular Diagnostics?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $746.46M compared with $113.23M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, ACHV or IMDX?
ACHV returned +118.07% over the past 12 months, compared with -5.98% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Insight Molecular Diagnostics in the same industry?
No. Achieve Life Sciences is in the Healthcare sector, while Insight Molecular Diagnostics is in Health Care.